Security
Genmab A/S ADS · GMAB
GMABNASDAQotherCurrentCIK 1434265Updated Nov 19, 2026
GMAB price & chart
Loading TradingView…
NASDAQ:GMAB on TradingView ↗About the company
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody - drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.
In the news
Financials
FY 2025 · USDSource
Source
Source
cash flow · annual statements
| Line item | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 | Q2 2019 | Q2 2018 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Profit or LossUSD | 336,000,000Source | 203,000,000Source | 1,335,000,000Source | 1,891,000,000Source | 306,000,000Source | 3,378,000,000Source | 85,000,000Source | 260,527,000Source | 963,000,000Source | 7,844,000,000Source | 4,352,000,000Source | 5,522,000,000Source |
| Additional Financial Items | ||||||||||||
| AdjustmentsForDeferredTaxOfPriorPeriodsUSD | — | — | — | — | — | — | — | — | -63,000,000Source | 99,000,000Source | -59,000,000Source | 107,000,000Source |
| AdjustmentsForFinanceCostsUSD | — | — | — | — | — | — | — | — | 269,000,000Source | 1,977,000,000Source | — | — |
| AdjustmentsForFinanceIncomeUSD | — | — | — | — | — | — | — | — | 408,000,000Source | 4,438,000,000Source | — | — |
| AdjustmentsForIncomeTaxExpenseUSD | — | — | — | — | — | — | — | — | -460,000,000Source | -343,000,000Source | -1,067,000,000Source | -1,583,000,000Source |
| AdjustmentsForSharebasedPaymentsUSD | — | — | — | — | — | — | — | — | 128,000,000Source | 721,000,000Source | 586,000,000Source | 439,000,000Source |
| GoodwillUSD | 355,000,000Source | 2,518,000,000Source | — | — | — | — | — | — | 355,000,000Source | 2,535,000,000Source | — | — |
| IncreaseDecreaseInWorkingCapitalDKK | — | — | — | — | — | — | — | — | — | — | -1,362,000,000Source | 1,930,000,000Source |
| InterestPaidClassifiedAsOperatingActivitiesUSD | — | — | — | — | — | — | — | — | 5,000,000Source | — | 1,000,000Source | 1,000,000Source |
| InterestReceivedClassifiedAsOperatingActivitiesUSD | — | — | — | — | — | — | — | — | 135,000,000Source | 935,000,000Source | 908,000,000Source | 283,000,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD | — | — | — | — | — | — | — | — | 13,000,000Source | 60,000,000Source | 91,000,000Source | 73,000,000Source |
| ProceedsFromBorrowingsClassifiedAsFinancingActivitiesUSD | — | — | — | — | — | — | — | — | 5,500,000,000Source | — | — | — |
| ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodUSD | — | — | — | — | — | — | — | — | 2,622,000,000Source | 11,279,000,000Source | 10,001,000,000Source | 7,254,000,000Source |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesUSD | — | — | — | — | — | — | — | — | 18,000,000Source | 117,000,000Source | 10,000,000Source | — |
| RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesUSD | — | — | — | — | — | — | — | — | 273,000,000Source | — | — | — |
| GeneralAndAdministrativeExpense | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 | Q2 2019 | Q2 2018 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cost of Goods and Services Sold | —Source | —Source | —Source | — | — | — | — | — | —Source | —Source | —Source | — |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — | — | — | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 144,000,000Source | 129,000,000Source | 827,000,000Source | 633,000,000Source | 264,000,000Source | — | — | — | 626,000,000Source | 3,790,000,000Source | 3,297,000,000Source | 2,676,000,000Source |
| Total RevenueUSD | 925,000,000Source | 779,000,000Source | 4,169,000,000Source | 3,162,000,000Source | 1,972,000,000Source | 5,451,000,000Source | 774,000,000Source | 509,675,000Source | 3,720,000,000Source | 21,526,000,000Source | 16,474,000,000Source | 14,595,000,000Source |
| Additional Financial Items | ||||||||||||
| ApplicableTaxRatenumber | — | — | — | — | — | — | — | — | 0.22Source | 0.22Source | 0.22Source | 0.22Source |
| AverageEffectiveTaxRatenumber | — | — | — | — | — | — | — | — | 0.2Source | 0.14Source | 0.23Source | 0.22Source |
| BasicEarningsLossPerShareUSD per share | 5.44Source | 3.15Source | 20.46Source | 28.87Source | 4.68Source | 51.88Source | 1.38Source | 4.26Source | 15.5Source | 122.21Source | 66.64Source | 84.45Source |
| CurrentTaxExpenseIncomeUSD | — | — | — | — | — | — | — | — | 256,000,000Source | 1,799,000,000Source | 1,301,000,000Source | 1,498,000,000Source |
| DeferredTaxExpenseIncomeRecognisedInProfitOrLossUSD | — | — | — | — | — | — | — | — | 10,000,000Source | — | — | — |
| DepreciationRightofuseAssetsUSD | 4,000,000Source | 4,000,000Source | 23,000,000Source | 16,000,000Source | — | — | — | — | 17,000,000Source | 102,000,000Source | 87,000,000Source | 74,000,000Source |
| DilutedEarningsLossPerShareUSD per share | 5.42Source | 3.13Source | 20.28Source | 28.66Source | 4.64Source | 51.35Source | 1.35Source | 4.21Source | 15.37Source | 121.36Source | 66.02Source | 83.65Source |
| EmployeeBenefitsExpenseUSD | — | — | — | — | — | — | — | — | 763,000,000Source | 4,344,000,000Source | 3,548,000,000Source | 2,583,000,000Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesUSD | — | — | — | — | — | — | — | — | 128,000,000Source | 721,000,000Source | 586,000,000Source | 439,000,000Source |
| FinanceCostsUSD | 91,000,000Source | 46,000,000Source | 120,000,000Source | 200,000,000Source | 430,000,000Source | 211,000,000Source | 60,000,000Source | — | 269,000,000Source | 1,977,000,000Source | 942,000,000Source | 680,000,000Source |
| FinanceIncomeUSD | 154,000,000Source | 117,000,000Source | 346,000,000Source | 1,442,000,000Source | 65,000,000Source | 42,000,000Source | 34,000,000Source | — | 408,000,000Source | 4,438,000,000Source | 1,258,000,000Source | 1,358,000,000Source |
| ImpairmentLossRecognisedInProfitOrLossGoodwillUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | — | — |
| IncomeTaxExpenseContinuingOperationsUSD | 87,000,000Source | 104,000,000Source | 359,000,000Source | 598,000,000Source | 116,000,000Source | 950,000,000Source | 26,000,000Source | 74,788,000Source | 241,000,000Source | 1,320,000,000Source | 1,285,000,000Source | 1,513,000,000Source |
| NetForeignExchangeLossDKK | 77,000,000Source | 17,000,000Source | 10,000,000Source | — | — | — | — | — | — | 1,594,000,000Source | 889,000,000Source | — |
| PostemploymentBenefitExpenseDefinedBenefitPlansUSD | — | — | — | — | — | — | — | — | 34,000,000Source | 205,000,000Source | 170,000,000Source | 112,000,000Source |
| ProfitLossBeforeTaxUSD | 423,000,000Source | 307,000,000Source | 1,694,000,000Source | 2,489,000,000Source | 422,000,000Source | 4,328,000,000Source | 111,000,000Source | 335,315,000Source | 1,204,000,000Source | 9,164,000,000Source | 5,637,000,000Source | 7,035,000,000Source |
| ProfitLossFromOperatingActivitiesUSD | 360,000,000Source | 236,000,000Source | 1,468,000,000Source | 1,247,000,000Source | 787,000,000Source | 4,497,000,000Source | 137,000,000Source | 135,044,000Source | 1,065,000,000Source | 6,703,000,000Source | 5,321,000,000Source | 6,357,000,000Source |
| ResearchAndDevelopmentExpenseUSD | 364,000,000Source | 361,000,000Source | 1,853,000,000Source | 1,282,000,000Source | 921,000,000Source | 775,000,000Source | 564,000,000Source | 318,889,000Source | 1,606,000,000Source | 9,748,000,000Source | 7,630,000,000Source | 5,562,000,000Source |
| GeneralAndAdministrativeExpense | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
| InterestExpenseOnLeaseLiabilities | — | — | —Source | —Source | — | — | — | — | — | — | — | — |
Filing attachments
gmab_20261110xex99d1.htm · 6-K · 2026-11-10
Exhibit 99.1 Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; November 10, 2026 - Genmab A/S (Nasdaq: GMAB) will increase its share capital by 164,828 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the Company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 2,961 shares at DKK 1,3…
Read attachment ↗gmab_20261028xex99d1.htm · 6-K · 2026-10-28
Exhibit 99.1 Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer Company Announcement COPENHAGEN, Denmark; October 28, 2026 • Phase 3 LiGeR-HN1 trial of Petosemtamab in combination with pembrolizumab versus pembrolizumab alone met both primary endpoints, reducing the risk of death by 50% in patients with PD-L1…
Read attachment ↗gmab_20261023xex99d1.htm · 6-K · 2026-10-23
Exhibit 99.1 Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer Company Announcement COPENHAGEN, Denmark; October 23, 2026 • Phase 3 RAINFOL™-02 trial met its primary endpoint of progression-free survival (PFS) and its key secondary endpoint of overall survival (OS) with rinatabart sesutecan (Rina-S®) compared to investigator’s choice chemothera…
Read attachment ↗gmab_20261013xex99d1.htm · 6-K · 2026-10-13
Exhibit 99.1 Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2026 Company Announcement • Net sales of DARZALEX® in the third quarter of 2026 totaled USD 4,239 million • Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; October 13, 2026 - Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) prod…
Read attachment ↗gmab_20261007xex99d1.htm · 6-K · 2026-10-07
Exhibit 99.1 Resolution Adopted at the Extraordinary General Meeting of Genmab A/S Including Grant of Restricted Stock Units to Board Members Company Announcement COPENHAGEN, Denmark; October 7, 2026 - Genmab A/S (Nasdaq: GMAB) Today, Genmab A/S held an Extraordinary General Meeting. At the Extraordinary General Meeting the proposal from the Board of Directors on remuneration of the Board of Directors for 2026, including share-based remuneration in the form of restricted stock units, was ap…
Read attachment ↗gmab_20261015xex99d1.htm · 6-K · 2026-10-05
Exhibit 99.1 Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Company Announcement COPENHAGEN, Denmark and NORTH CHICAGO, Ill.; October 5, 2026 • EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free surv…
Read attachment ↗